{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:33Z","timestamp":1787009853232,"version":"build-2736575974"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n                  <jats:p>Obstetrician\u2013gynecologists frequently are consulted either before the initiation of cancer treatment to request menstrual suppression or during an episode of severe heavy bleeding to stop bleeding emergently. Adolescents presenting emergently with severe uterine bleeding usually require only medical management; surgical management rarely is required. Surgical management should be considered for patients who are not clinically stable, or for those whose conditions are not suitable for medical management or have failed to respond appropriately to medical management. When used continuously, combined hormonal contraceptives are effective for producing amenorrhea, although complete amenorrhea cannot be guaranteed. The risk of venous thromboembolism in patients with cancer is compounded by multiple factors, including presence of metastatic or fast-growing, biologically aggressive cancers; hematologic cancers; treatment-related factors such as surgery or central venous catheters; and the number and type of comorbid conditions. Although as a group, patients undergoing cancer treatment are at elevated risk of venous thromboembolism compared with the general population, this risk may be extremely elevated for certain patients and existing guidance on risk stratification should be consulted. The decision to use estrogen in patients with cancer should be tailored to the individual patient after collaborative consideration of the risk\u2013benefit ratio with the patient and the health care team; the patient should be closely monitored for known adverse effects such as liver toxicity and venous thromboembolism.<\/jats:p>","DOI":"10.1097\/aog.0000000000004209","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:43:30Z","timestamp":1608317010000},"page":"e7-e15","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Options for Prevention and Management of Menstrual Bleeding in Adolescent Patients Undergoing Cancer Treatment"],"prefix":"10.1097","volume":"137","member":"276","reference":[{"key":"R1-20260601","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/AOG.0000000000001031","article-title":"Hormone use for therapeutic amenorrhea and contraception during hematopoietic cell transplantation","volume":"126","author":"Chang","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R2-20260601","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jogc.2018.11.030","article-title":"No. 313-menstrual suppression in special circumstances","volume":"41","author":"Kirkham","year":"2019","journal-title":"J Obstet Gynaecol Can"},{"key":"R3-20260601","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1097\/AOG.0000000000002763","article-title":"Gynecologic issues in children and adolescent cancer patients and survivors. ACOG Committee Opinion No. 747. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R4-20260601","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0010-7824(00)00182-7","article-title":"Menstruation: choosing whether...and when","volume":"62","author":"Kaunitz","year":"2000","journal-title":"Contraception"},{"key":"R5-20260601","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","article-title":"Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation","volume":"92","author":"H\u00e4gglund","year":"1998","journal-title":"Blood"},{"key":"R6-20260601","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","article-title":"The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention","volume":"112","author":"Gerber","year":"2008","journal-title":"Blood"},{"key":"R7-20260601","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1538-7836.2008.03077.x","article-title":"Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation","volume":"6","author":"Gonsalves","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R8-20260601","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R9-20260601","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fped.2017.00012","article-title":"Venous thromboembolism in children with cancer and blood disorders","volume":"5","author":"Ko","year":"2017","journal-title":"Front Pediatr"},{"key":"R10-20260601","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/(SICI)1096-8652(199603)51:3<248::AID-AJH17>3.0.CO;2-C","article-title":"Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis","volume":"51","author":"Sica","year":"1996","journal-title":"Am J Hematol"},{"key":"R11-20260601","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1479-828X.1997.tb02260.x","article-title":"High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents","volume":"37","author":"Aksu","year":"1997","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R12-20260601","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/OGX.0b013e31820955be","article-title":"Gynecologic care in hematopoietic stem cell transplant patients: a review","volume":"65","author":"Milroy","year":"2010","journal-title":"Obstet Gynecol Surv"},{"issue":"RR-3","key":"R13-20260601","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R14-20260601","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/pbc.23360","article-title":"The management of menstrual suppression and uterine bleeding: a survey of current practices in the Pediatric Blood and Marrow Transplant Consortium","volume":"59","author":"Adegite","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20260601","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/cncr.22199","article-title":"Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate","volume":"107","author":"Meirow","year":"2006","journal-title":"Cancer"},{"key":"R16-20260601","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.bmt.1701187","article-title":"Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation","volume":"21","author":"Chiusolo","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R17-20260601","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/AOG.0b013e31827374e2","article-title":"Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial","volume":"121","author":"Elgindy","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R18-20260601","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdq066","article-title":"No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group","volume":"21","author":"Behringer","year":"2010","journal-title":"Ann Oncol"},{"key":"R20-20260601","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejogrb.2007.03.012","article-title":"Prevention and treatment of uterine bleeding in hematologic malignancy","volume":"134","author":"Quaas","year":"2007","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R21-20260601","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpag.2015.10.013","article-title":"Use and effectiveness of gonadotropin-releasing hormone agonists for prophylactic menstrual suppression in postmenarchal women who undergo hematopoietic cell transplantation","volume":"29","author":"Poorvu","year":"2016","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R22-20260601","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.fertnstert.2008.09.077","article-title":"Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists","volume":"91","author":"Bedaiwy","year":"2009","journal-title":"Fertil Steril"},{"key":"R23-20260601","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ajh.2830420404","article-title":"Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation","volume":"42","author":"Ghalie","year":"1993","journal-title":"Am J Hematol"},{"key":"R24-20260601","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1592\/phco.31.11.1092","article-title":"Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy","volume":"31","author":"Bates","year":"2011","journal-title":"Pharmacotherapy"},{"key":"R25-20260601","first-page":"537","article-title":"Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate","volume":"42","author":"Laufer","year":"1997","journal-title":"J Reprod Med"},{"key":"R26-20260601","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3109\/10428190109097723","article-title":"Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study","volume":"42","author":"Lhomm\u00e9","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"R27-20260601","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jpag.2007.04.008","article-title":"Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis","volume":"20","author":"Divasta","year":"2007","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R28-20260601","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0029-7844(97)00620-0","article-title":"Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group","volume":"91","author":"Hornstein","year":"1998","journal-title":"Obstet Gynecol"},{"key":"R29-20260601","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpag.2016.02.008","article-title":"The effects of gonadotropin-releasing hormone agonist combined with add-back therapy on quality of life for adolescents with endometriosis: a randomized controlled trial","volume":"30","author":"Sadler Gallagher","year":"2017","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R30-20260601","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/AOG.0000000000000964","article-title":"Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial","volume":"126","author":"DiVasta","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R32-20260601","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jogc.2015.12.003","article-title":"Canadian Contraception Consensus (part 3 of 4): chapter 8 - progestin-only contraception","volume":"38","author":"Black","year":"2016","journal-title":"J Obstet Gynaecol Can"},{"key":"R33-20260601","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/AOG.0000000000003411","article-title":"Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding. ACOG Committee Opinion No. 785. American College of Obstetricians and Gynecologists","volume":"134","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R34-20260601","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1196\/annals.1429.020","article-title":"Menstrual issues in adolescents with physical and developmental disabilities","volume":"1135","author":"Quint","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R35-20260601","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.contraception.2006.03.008","article-title":"Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg","volume":"74","author":"Arias","year":"2006","journal-title":"Contraception"},{"issue":"RR-4","key":"R36-20260601","first-page":"1","article-title":"U.S. selected practice recommendations for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R37-20260601","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOP.0000000000000359","article-title":"Menstrual management and reproductive concerns in adolescent and young adult women with underlying hematologic or oncologic disease","volume":"28","author":"Quinn","year":"2016","journal-title":"Curr Opin Pediatr"},{"key":"R38-20260601","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2012.05.008","article-title":"Cancer and contraception. Release date May 2012. SFP Guideline #20121. Society of Family Planning","volume":"86","author":"Patel","year":"2012","journal-title":"Contraception"},{"key":"R39-20260601","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1471-0528.1998.tb10172.x","article-title":"Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia","volume":"105","author":"Irvine","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"R40-20260601","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajog.2015.07.044","article-title":"The medical management of abnormal uterine bleeding in reproductive-aged women","volume":"214","author":"Bradley","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R42-20260601","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jpag.2016.04.001","article-title":"Levonorgestrel-releasing intrauterine device use in female adolescents with heavy menstrual bleeding and bleeding disorders: single institution review","volume":"30","author":"Adeyemi-Fowode","year":"2017","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R43-20260601","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.fertnstert.2008.02.140","article-title":"Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials","volume":"91","author":"Darney","year":"2009","journal-title":"Fertil Steril"},{"key":"R44-20260601","first-page":"653","article-title":"Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial","volume":"101","author":"Miller","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R45-20260601","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jpag.2018.02.130","article-title":"Treatment modalities in adolescents who present with heavy menstrual bleeding","volume":"31","author":"Alaqzam","year":"2018","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R46-20260601","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00043426-199909000-00019","article-title":"Oral contraceptives: a cause of hyperbilirubinemia in stem cell transplant patients","volume":"21","author":"Kline","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"R47-20260601","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.AOG.0000428646.67925.9a","article-title":"Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Committee Opinion No. 557. American College of Obstetricians and Gynecologists","volume":"121","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R48-20260601","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4274\/jcrpe.0014","article-title":"Abnormal uterine bleeding in adolescents","volume":"10","author":"Elmao\u011fullar\u0131","year":"2018","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"R49-20260601","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/01.AOG.0000238343.62063.22","article-title":"Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial","volume":"108","author":"Munro","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R50-20260601","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0010-7824(97)00174-1","article-title":"In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women","volume":"56","author":"Kuhnz","year":"1997","journal-title":"Contraception"},{"key":"R51-20260601","doi-asserted-by":"crossref","first-page":"499.e1","DOI":"10.1016\/j.ajog.2013.02.013","article-title":"A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study","volume":"208","author":"Ammerman","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"R53-20260601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.contraception.2018.02.008","article-title":"Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception?","volume":"98","author":"Thorne","year":"2018","journal-title":"Contraception"},{"key":"R54-20260601","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/GCO.0000000000000394","article-title":"Evaluation and management of heavy menstrual bleeding in adolescents","volume":"29","author":"Moon","year":"2017","journal-title":"Curr Opin Obstet Gynecol"}],"updated-by":[{"DOI":"10.1097\/aog.0000000000005034","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000}},{"DOI":"10.1097\/aog.0000000000005245","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}},{"DOI":"10.1097\/aog.0000000000004875","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000}}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:01:37Z","timestamp":1780326097000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004209"}},"subtitle":["ACOG Committee Opinion, Number 817"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004209","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}